Stockscreener 앱 받기
8.71
1.99%
0.17
전일 마감가:
$8.54
열려 있는:
$8.61
하루 거래량:
1.06M
Relative Volume:
1.88
시가총액:
$590.09M
수익:
$568.09M
순이익/손실:
$27.27M
주가수익비율:
26.59
EPS:
0.3276
순현금흐름:
$71.41M
1주 성능:
+0.35%
1개월 성능:
-18.06%
6개월 성능:
+13.12%
1년 성능:
+35.46%
1일 변동 폭
$8.61
$8.86
1주일 범위
$8.39
$8.86
52주 변동 폭
$5.81
$11.25
Bioventus Inc Stock (BVS) Company Profile
명칭
Bioventus Inc
전화
(919) 474-6700
주소
4721 EMPEROR BOULEVARD, SUITE 100, DURHAM
Compare BVS vs ABT, SYK, MDT, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BVS
Bioventus Inc
|
8.71 | 590.09M | 568.09M | 27.27M | 71.41M | 0.3276 |
ABT
Abbott Laboratories
|
88.41 | 153.99B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
307.80 | 118.00B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
79.34 | 101.86B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
45.29 | 67.32B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
87.36 | 50.30B | 6.30B | 1.07B | 1.09B | 1.8406 |
Bioventus Inc Stock (BVS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-27 | 개시 | CJS Securities | Market Outperform |
| 2026-02-09 | 개시 | Barrington Research | Outperform |
| 2025-07-07 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-12-17 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2023-12-07 | 업그레이드 | Canaccord Genuity | Hold → Buy |
| 2023-08-09 | 업그레이드 | Craig Hallum | Hold → Buy |
| 2022-11-22 | 다운그레이드 | Craig Hallum | Buy → Hold |
| 2022-11-09 | 다운그레이드 | Canaccord Genuity | Buy → Hold |
| 2022-11-09 | 다운그레이드 | JP Morgan | Overweight → Underweight |
| 2022-03-15 | 개시 | Craig Hallum | Buy |
| 2021-11-15 | 재개 | Morgan Stanley | Overweight |
| 2021-11-10 | 재개 | JP Morgan | Overweight |
| 2021-07-01 | 다운그레이드 | Goldman | Buy → Neutral |
| 2021-03-08 | 개시 | Canaccord Genuity | Buy |
| 2021-03-08 | 개시 | Goldman | Buy |
| 2021-03-08 | 개시 | JP Morgan | Overweight |
| 2021-03-08 | 개시 | Morgan Stanley | Overweight |
모두보기
Bioventus Inc 주식(BVS)의 최신 뉴스
Precision Trading with Bioventus Inc. (BVS) Risk Zones - Stock Traders Daily
Bioventus Inc (BVS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Bioventus Inc (BVS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Bioventus Inc (BVS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Bioventus Inc (BVS) Institutional Confidence - TradingKey
Bioventus Inc (BVS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Bioventus Inc (BVS) Valuation: PE, PB & Fair Value Analysis - TradingKey
Bioventus Inc (BVS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Bioventus Inc (BVS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Bioventus Inc (BVS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
EBIT per share of Bioventus, Inc. Class A – TRADEGATE:4B8 - TradingView
After tax other income/expense of Bioventus, Inc. Class A – TRADEGATE:4B8 - TradingView
Bioventus, Inc. Class A Statistics – TRADEGATE:4B8 - TradingView
Bioventus, Inc. Class A Trade Ideas — TRADEGATE:4B8 - TradingView
BVS Maintained by Canaccord Genuity -- Price Target Stays at $15 - GuruFocus
Canaccord reiterates Bioventus stock rating on growth strategy - Investing.com
Canaccord reiterates Bioventus stock rating on growth strategy By Investing.com - Investing.com Canada
Bioventus Inc. (BVS) Q1 2026 Earnings: Strong EPS Beat Despite Stock DeclineEarnings Miss Streak - newsline.com
Bioventus highlights PNS, PRP growth as cash flow improves and debt falls - MSN
Are Investors Undervaluing Bioventus (BVS) Right Now? - Yahoo Finance
Bioventus (BVS) Edges Lower as Stock Tests Support ZoneGamma Squeeze - newsline.com
Bioventus Highlights PNS, PRP Growth as Cash Flow Improves and Debt Falls - sharewise.com
Bioventus (BVS) Goldman Sachs 47th Annual Global Healthcare Conference 2026 summary - Quartr
Bioventus Inc at Goldman Sachs Healthcare Conference Transcript - GuruFocus
Technical Reactions to BVS Trends in Macro Strategies - Stock Traders Daily
BVS SEC FilingsBioventus Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Bioventus (BVS) director and 10% owner reports RSU grant and vesting-related share exercise - Stock Titan
Bioventus (NASDAQ: BVS) director Sutter awarded 25,146 RSUs and exercises 32,282 shares - Stock Titan
Bioventus (BVS) director granted RSUs and exercises prior awards - Stock Titan
Bioventus (BVS) director exercises RSUs and holds 148,892 shares - Stock Titan
Bioventus (BVS) director receives 25,146 RSUs and converts 32,282 into shares - Stock Titan
Bioventus (BVS) director McMurry-Heath gains shares via RSU vesting and new grant - Stock Titan
[Form 4] Bioventus Inc. Insider Trading Activity - Stock Titan
Bioventus (BVS) director Hawkins granted 30,994 RSUs and exercises 39,789 into shares - Stock Titan
Bioventus (BVS) director granted 25,146 RSUs and exercises 32,282 into shares - Stock Titan
Bioventus (BVS) director Pat Beyer receives 25,146 RSUs and converts 32,282 into Class A shares - Stock Titan
Bioventus Q1 2026 slides: earnings beat drives guidance raise - Investing.com
Bioventus Shareholders Back Directors and Auditor at 2026 Meeting - TipRanks
Bioventus (BVS) 2026 meeting re-elects full board and ratifies auditor - Stock Titan
Bioventus (BVS) Q1 2026 Earnings Transcript - AOL.com
After Plunging 22% in 4 Weeks, Here's Why the Trend Might Reverse for Bioventus (BVS) - Yahoo Finance
Bioventus (BVS) may find a bottom soon, here's why you should buy the stock now - MSN
Bioventus to Present at the Goldman Sachs 47TH Annual Global Healthcare Conference - The Manila Times
Watch Bioventus' CFO in a live Goldman Sachs healthcare fireside chat - Stock Titan
Transcript: Bioventus Q1 2026 Earnings Conference Call - Benzinga
BVS Q1 2026 Earnings: Strong EPS Beat Overshadowed by Market SkepticismAnalyst Coverage Count - The Legal Advocate
BVS Q1 2026 Earnings: EPS Beats Estimates by 52.3% Despite Stock DeclineEarnings Analysis - The Legal Advocate
Bioventus (BVS) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - sharewise.com
Bioventus Inc. (BVS) Holds Steady Near Support as Consolidation PersistsBlock Trade Flow - newsline.com
Number of shareholders of Bioventus Inc. – NASDAQ:BVS - TradingView
Is Bioventus (BVS) stock undervalued right now? - MSN
Bioventus Inc (BVS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.93%
자본화:
|
볼륨(24시간):